Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Other Accumulated Expenses (2022 - 2026)

TriSalus Life Sciences has reported Other Accumulated Expenses over the past 5 years, most recently at $269000.0 for Q1 2026.

  • For Q1 2026, Other Accumulated Expenses fell 36.85% year-over-year to $269000.0; the TTM value through Mar 2026 reached $269000.0, down 36.85%, while the annual FY2025 figure was $234000.0, 38.9% down from the prior year.
  • Other Accumulated Expenses for Q1 2026 was $269000.0 at TriSalus Life Sciences, up from $234000.0 in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $427000.0 in Q3 2023 and troughed at $142000.0 in Q4 2022.
  • A 5-year average of $299583.3 and a median of $280000.0 in 2024 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: soared 173.94% in 2023 and later tumbled 38.9% in 2025.
  • Year by year, Other Accumulated Expenses stood at $142000.0 in 2022, then soared by 173.94% to $389000.0 in 2023, then dropped by 1.54% to $383000.0 in 2024, then tumbled by 38.9% to $234000.0 in 2025, then increased by 14.96% to $269000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for TLSI at $269000.0 in Q1 2026, $234000.0 in Q4 2025, and $224000.0 in Q3 2025.